Omar F. KhanProfile page
Assistant Professor
Faculty of Applied Science and Engineering, Institute of Biomedical Engineering
Orcid identifier0000-0003-3811-2369
- Assistant ProfessorFaculty of Applied Science and Engineering, Institute of Biomedical Engineering
- 164 College St, Rosebrugh Building, RM420, Toronto, Ontario, M5S 3G9, Canada
BIO
Dr. Khan is an Assistant Professor at the Institute of Biomedical Engineering. He is the Canada Research Chair in Nucleic Acid Therapeutics. He earned his B.A.Sc. and Ph.D. in Chemical Engineering and Applied Chemistry from the University of Toronto, and his academic supervisor was Professor Michael V. Sefton. He later joined the laboratories of Professors Daniel G. Anderson and Robert Langer as a Postdoctoral Associate in the Massachusetts Institute of Technology. Professor Khan was also the Scientific Founder and Chief Scientist of Tiba Biotech, a Boston-area company spun out from his postdoctoral research. As an mRNA nanotechnology and vaccine expert, he is regularly featured in television, radio and print news.
His early career focused on the creation of three dimensional organoid models and engineered tissue substitutes. This work evolved to include the development of nucleic acid-based platform technologies and novel biomaterials to study the genetic mechanisms of diseases and create RNA-based therapies. Now, Professor Khan endeavors to contribute to Canada’s growing research-to-translation ecosystem by creating new regenerative medicine-enabling technologies, and training highly qualified personnel capable of addressing diverse local and global bioengineering needs.
His early career focused on the creation of three dimensional organoid models and engineered tissue substitutes. This work evolved to include the development of nucleic acid-based platform technologies and novel biomaterials to study the genetic mechanisms of diseases and create RNA-based therapies. Now, Professor Khan endeavors to contribute to Canada’s growing research-to-translation ecosystem by creating new regenerative medicine-enabling technologies, and training highly qualified personnel capable of addressing diverse local and global bioengineering needs.
ACADEMIC POSITIONS
- Associate Director Research, Biomedical EngineeringUniversity of Toronto, Toronto, Canada16 Sep 2022 - present
- Assistant ProfessorUniversity of Toronto, Institute of Biomedical Engineering, Toronto, CanadaMay 2020 - present
- Assistant ProfessorUniversity of Toronto, Immunology, Toronto, Canada1 May 2020 - present
- Medicine by Design InvestigatorUniversity of Toronto, Toronto, CanadaMay 2020 - present
- Research ScientistMassachusetts Institute of Technology, Cambridge, United StatesApr 2016 - Dec 2017
- Teaching AssistantUniversity of Toronto, Toronto, CanadaSep 2004 - May 2010
- Course InstructorUniversity of Toronto, Engineering Outreach Office, Toronto, CanadaJun 2004 - Jul 2009
- Undergraduate Research FellowUniversity of Toronto, Toronto, CanadaMay 2002 - Sep 2002
NON-ACADEMIC POSITIONS
- Founder & DirectorAzane Therapeutics24 Nov 2022 - present
- Principal ConsultantIndependent Consultant, Greater Boston, United StatesAug 2019 - 1 May 2020
- Scientific Founder & Chief ScientistTiba Biotech, Greater Boston, United StatesJan 2018 - Jul 2019
- Engineer InternPetro-Canada Lubricants, Mississauga, CanadaAug 2002 - Sep 2003
DEGREES
- PhD, Chemical and Biomedical EngineeringUniversity of Toronto, Toronto, Canada2006 - 2010
- MASc, Chemical and Biomedical EngineeringUniversity of Toronto, Toronto, Canada2004 - 2006
POSTGRADUATE TRAINING
- Postdoctoral AssociateMassachusetts Institute of Technology, Cambridge, United States2011 - 2016Nucleic acid delivery, biomaterials, neuromuscular implantsPostdoctoral Research
INSTITUTIONAL STRATEGIC INITIATIVES
- EPIC (Emerging and Pandemic Infections Consortium)
- Medicine by Design (MbD)
- PRiME (Precision Medicine Initiative)
- Institute for Pandemics (IfP)